Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12824) 12824
Publication (1598) 1598
Newsletter (822) 822
Book Review (314) 314
Magazine Article (141) 141
Book Chapter (93) 93
Newspaper Article (70) 70
Transcript (24) 24
Conference Proceeding (16) 16
Book / eBook (11) 11
Trade Publication Article (8) 8
Dissertation (4) 4
Data Set (3) 3
Presentation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
corticosteroids (11414) 11414
index medicus (7951) 7951
humans (7585) 7585
male (4846) 4846
female (4417) 4417
animals (3728) 3728
steroids (2935) 2935
adult (2702) 2702
analysis (2637) 2637
middle aged (2078) 2078
neurosciences (1862) 1862
asthma (1826) 1826
pharmacology & pharmacy (1764) 1764
glucocorticoids (1533) 1533
stress (1533) 1533
research (1500) 1500
endocrinology & metabolism (1401) 1401
care and treatment (1393) 1393
immunology (1363) 1363
cortisol (1331) 1331
aged (1319) 1319
inflammation (1259) 1259
health aspects (1172) 1172
rats (1112) 1112
drug therapy (1095) 1095
medicine & public health (1091) 1091
physiological aspects (1086) 1086
adolescent (1081) 1081
treatment outcome (1068) 1068
psychiatry (1044) 1044
article (999) 999
asthma - drug therapy (970) 970
young adult (959) 959
mice (940) 940
inhaled corticosteroids (925) 925
risk factors (923) 923
dexamethasone (889) 889
child (860) 860
hormones (819) 819
gene expression (818) 818
allergy (805) 805
medical research (797) 797
children (784) 784
expression (777) 777
therapy (774) 774
respiratory system (771) 771
drugs (751) 751
internal medicine (708) 708
adrenal cortex hormones - therapeutic use (696) 696
glucocorticoids - pharmacology (674) 674
biochemistry & molecular biology (672) 672
medicine (671) 671
hydrocortisone - blood (666) 666
time factors (664) 664
double-blind (662) 662
brain (657) 657
dose-response relationship, drug (643) 643
medicine, experimental (638) 638
proteins (635) 635
administration, inhalation (630) 630
glucocorticoids - therapeutic use (624) 624
double-blind method (623) 623
studies (619) 619
research article (612) 612
dosage and administration (610) 610
cancer (606) 606
receptors, glucocorticoid - metabolism (598) 598
pregnancy (597) 597
cytokines (578) 578
cell biology (575) 575
patients (570) 570
hydrocortisone - metabolism (563) 563
pituitary-adrenal axis (541) 541
medical colleges (540) 540
clinical trials (537) 537
mortality (534) 534
disease (532) 532
dexamethasone - pharmacology (528) 528
pediatrics (526) 526
drug therapy, combination (525) 525
hydrocortisone (520) 520
physiology (518) 518
abridged index medicus (505) 505
rodents (502) 502
genetic aspects (500) 500
adrenal cortex hormones - administration & dosage (493) 493
gene-expression (488) 488
universities and colleges (488) 488
aldosterone (479) 479
corticoids (476) 476
behavioral sciences (475) 475
genes (473) 473
glucocorticoids - administration & dosage (471) 471
multidisciplinary sciences (465) 465
glucocorticoid receptor (464) 464
prednisone (463) 463
oncology (462) 462
depression (457) 457
corticosteroid (445) 445
prednisolone (443) 443
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13939) 13939
French (25) 25
German (11) 11
Japanese (3) 3
Spanish (3) 3
Polish (2) 2
Turkish (2) 2
Chinese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Aprepitant and fosaprepitant drug interactions: a systematic review
by Patel, Priya and Leeder, J. Steven and Piquette‐Miller, Micheline and Dupuis, L. Lee
British Journal of Clinical Pharmacology, ISSN 0306-5251, 10/2017, Volume 83, Issue 10, pp. 2148 - 2162
Aims Aprepitant and fosaprepitant, commonly used for the prevention of chemotherapy‐induced nausea and vomiting, alter cytochrome P450 activity. This... 
aprepitant | drug–drug interactions | fosaprepitant | METHYLENE-BLUE | CHEMOTHERAPY-INDUCED NAUSEA | SITE ADVERSE EVENTS | CYTOCHROME-P450 3A4 | IFOSFAMIDE | drug-drug interactions | CANCER-PATIENTS | CONCISE GUIDE | PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | INDUCED NEUROTOXICITY | RECEPTOR ANTAGONIST APREPITANT | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Nausea - chemically induced | Humans | Antineoplastic Agents - therapeutic use | Drug Interactions | Cytochrome P-450 CYP2C9 Inducers - pharmacology | Antiemetics - therapeutic use | Antineoplastic Agents - pharmacology | Vomiting - prevention & control | Morpholines - therapeutic use | Quetiapine Fumarate - pharmacology | Aprepitant | Oxycodone - therapeutic use | Oxycodone - pharmacology | Injection Site Reaction - etiology | Serotonin Uptake Inhibitors - therapeutic use | Morpholines - pharmacology | Quetiapine Fumarate - therapeutic use | Nausea - prevention & control | Vomiting - chemically induced | Ethanol - pharmacology | Serotonin and Noradrenaline Reuptake Inhibitors - pharmacology | Cytochrome P-450 CYP2C9 Inducers - therapeutic use | Serotonin and Noradrenaline Reuptake Inhibitors - therapeutic use | Cytochrome P-450 CYP3A Inhibitors - therapeutic use | Antiemetics - pharmacology | Complications and side effects | Anthracyclines | Chemotherapy | Corticosteroids | Gastrointestinal agents | Drug interactions | Nausea | Cancer | Index Medicus | Systematic Review and Meta–Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma
by Kroiss, Matthias and Quinkler, Marcus and Lutz, Werner K and Allolio, Bruno and Fassnacht, Martin
Clinical Endocrinology, ISSN 0300-0664, 11/2011, Volume 75, Issue 5, pp. 585 - 591
Summary Mitotane [1‐(2‐chlorophenyl)‐1‐(4‐chlorophenyl)‐2,2‐dichloroethane, (o,p’‐DDD)] is the only drug approved for the treatment for adrenocortical... 
PREGNANE X RECEPTOR | CYTOCHROME-P450 3A | PHASE-II TRIAL | IN-VITRO | ENZYME-INDUCTION | DOXORUBICIN | ENDOCRINOLOGY & METABOLISM | KETOCONAZOLE | HUMAN LIVER-MICROSOMES | ADRENAL-CORTICAL CARCINOMA | CORTISOL | Pyrroles - pharmacokinetics | Humans | Antineoplastic Agents - therapeutic use | Adrenocortical Carcinoma - enzymology | Mitotane - therapeutic use | Mitotane - pharmacokinetics | Adrenocortical Carcinoma - drug therapy | Animals | Drug Interactions | Cytochrome P-450 CYP3A - metabolism | Adrenocortical Carcinoma - metabolism | Indoles - pharmacokinetics | Indoles - therapeutic use | Antineoplastic Agents - pharmacokinetics | Pyrroles - therapeutic use | Care and treatment | Carcinoma | Corticosteroids | Simvastatin | Drug interactions | Cytochrome P-450 | Pravastatin | Drug approval | Complications and side effects | Mitotane | Physiological aspects | Dosage and administration | Universities and colleges | Cancer | Clinical trials | Metabolism | Medical research | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method
by van Leeuwen, R.W.F and Swart, E.L and Boven, E and Boom, F.A and Schuitenmaker, M.G and Hugtenburg, J.G
Annals of Oncology, ISSN 0923-7534, 2011, Volume 22, Issue 10, pp. 2334 - 2341
Background: In cancer patients, drug interactions may intensify adverse events or reduce antitumour effects. We assessed the prevalence of potential drug... 
Chemotherapy | Drug interactions | Risk factors | RHEUMATOID-ARTHRITIS | FALLS | risk factors | drug interactions | CYCLOPHOSPHAMIDE | RISK | chemotherapy | ELDERLY PERSONS | PHARMACOKINETICS | ONCOLOGY | WARFARIN | ORAL CORTICOSTEROIDS | MEDICAL PATIENTS | Cross-Sectional Studies | Nonprescription Drugs - pharmacology | Humans | Middle Aged | Risk Factors | Male | Antineoplastic Agents - administration & dosage | Drug Monitoring - methods | Neoplasms - drug therapy | Nonprescription Drugs - administration & dosage | Young Adult | Drug Interactions | Aged, 80 and over | Adult | Female | Aged | Antineoplastic Agents - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Clinically Significant Drug-Drug Interactions Involving Medications Used for Symptom Control in Patients With Advanced Malignant Disease: A Systematic Review
by Kotlinska-Lemieszek, Aleksandra and Klepstad, Pål and Haugen, Dagny Faksvåg
Journal of Pain and Symptom Management, ISSN 0885-3924, 2019, Volume 57, Issue 5, pp. 989 - 989
Context: Most patients with advanced malignant disease need to take several drugs to control symptoms. This treatment raises risks of serious adverse effects... 
symptoms | Pharmacotherapy | drug-drug interactions | patients with cancer | palliative care | ADVANCED CANCER | DEXAMETHASONE | METHOTREXATE | ACUTE-RENAL-FAILURE | DECREASED PHENYTOIN LEVEL | CHEMOTHERAPY | CLINICAL NEUROLOGY | INDUCED RHABDOMYOLYSIS | MEDICINE, GENERAL & INTERNAL | SEROTONIN TOXICITY | THERAPY | HEALTH CARE SCIENCES & SERVICES | Delirium | High risk | Physicians | Liver | Central nervous system | Nervous system | Systematic review | Sedation | Bleeding | Neuroleptic malignant syndrome | Pain | Databases | Analgesics | Opioids | Ataxia | Malignant | Antidepressant drugs | Seizures | Heart arrhythmia | Corticosteroids | Publications | Critical incidents | Metabolism | Kidney failure | Citations | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Using known drug interactions to manage supratherapeutic calcineurin inhibitor concentrations
by Lange, Nicholas W and Salerno, David M and Berger, Karen and Tsapepas, Demetra S
Clinical Transplantation, ISSN 0902-0063, 11/2017, Volume 31, Issue 11, pp. e13098 - n/a
Objectives To summarize the available body of evidence guiding the management of supratherapeutic concentrations of calcineurin inhibitors (CNI) using... 
side effects | complication | immunosuppressant | calcineurin inhibitor | pharmacokinetics/pharmacodynamics | SOLID-ORGAN TRANSPLANTATION | SURGERY | OVERDOSE | INDUCTION | CLINICAL PHARMACOKINETICS | TRANSPLANTATION | CYCLOSPORINE-A | PHENYTOIN | FK-506 | CORTICOSTEROIDS | ACUTE TACROLIMUS TOXICITY | Graft Rejection - drug therapy | Graft Rejection - etiology | Drug Interactions | Calcineurin Inhibitors - therapeutic use | Humans | Kidney Transplantation - adverse effects | Complications and side effects | Usage | Anticonvulsants | Tacrolimus | Drug interactions | Cytochrome P-450 | Rifampin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Potential drug–drug interactions in hospitalised haematological patients
by Fernández de Palencia Espinosa, Ma Ángeles and Díaz Carrasco, Ma Sacramento and Sánchez Salinas, Andrés and de la Rubia Nieto, Amelia and Miró, Alberto Espuny
Journal of Oncology Pharmacy Practice, ISSN 1078-1552, 9/2017, Volume 23, Issue 6, pp. 443 - 453
Background Frequently, haematological patients undergo highly complex and intensive treatment protocols, so a high risk of drug–drug interactions could be... 
haematological | Drug-drug interaction | chemotherapy | inpatient | OMEPRAZOLE-CYCLOSPORINE INTERACTION | INTENSIVE-CARE UNITS | TRANSPLANT RECIPIENTS | PREVALENCE | CANCER-PATIENTS | ONCOLOGY | PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | MYCOPHENOLATE-MOFETIL | FLUCONAZOLE | Prospective Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Risk Factors | Logistic Models | Male | Azoles - therapeutic use | Antifungal Agents - therapeutic use | Drug Interactions | Female | Aged | Databases, Factual | Drugs | Corticoids | Fungicides | Identification methods | Multivariate analysis | Data bases | Risk factors | Immunosuppressive agents | Databases | Antidepressants | Classification | Drug interaction | Statins | Sheets | Antineoplastic drugs | Statistical analysis | Corticosteroids | Hematology | Drug interactions | Antifungal agents | Regression analysis | Risk analysis | Patients | Studies | Antiemetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Potential drug–drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France
by Bonnet, Clément and Boudou-Rouquette, Pascaline and Azoulay-Rutman, Esther and Huillard, Olivier and Golmard, Jean-Louis and Carton, Edith and Noé, Gaëlle and Vidal, Michel and Orvoen, Galdric and Chah Wakilian, Anne and Villeminey, Clémentine and Blanchet, Benoit and Alexandre, Jérôme and Goldwasser, François and Thomas-Schoemann, Audrey
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 05/2017, Volume 79, Issue 5, pp. 1051 - 1055
Abiraterone acetate combined with prednisone improves survival in metastatic castration-resistant prostate cancer (mCRPC) patients. This oral anticancer agent... 
Pharmacist | Prevalence | Abiraterone | Prostate cancer | Drug–drug interactions | MANAGEMENT | CHEMOTHERAPY | PHARMACOKINETICS | ONCOLOGY | PHARMACOLOGY & PHARMACY | Drug-drug interactions | AGENTS | ACETATE | POLYPHARMACY | Enzyme Inhibitors - adverse effects | France - epidemiology | Androstenes - adverse effects | Cross-Sectional Studies | Pain - epidemiology | Comorbidity | Humans | Androstenes - therapeutic use | Male | Pain - chemically induced | Prostatic Neoplasms, Castration-Resistant - drug therapy | Enzyme Inhibitors - therapeutic use | Disease-Free Survival | Neoplasm Metastasis | Drug Interactions | Polypharmacy | Aged, 80 and over | Aged | Retrospective Studies | Pharmacists | Prostatic Neoplasms, Castration-Resistant - epidemiology | Electronic Health Records | Complications and side effects | Cancer patients | Care and treatment | Corticosteroids | Analysis | Drug interactions | Oncology, Experimental | Medical records | Metastasis | Research | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Stress, alcohol and drug interaction: an update of human research
by Uhart, Magdalena and Wand, Gary S
Addiction Biology, ISSN 1355-6215, 01/2009, Volume 14, Issue 1, pp. 43 - 64
A challenging question that continues unanswered in the field of addiction is why some individuals are more vulnerable to substance use disorders than others.... 
stress | glucocorticoids | Addiction | alcoholism | reward system | dopamine | Dopamine | Glucocorticoids | Reward system | Alcoholism | Stress | CONDITIONED PLACE PREFERENCE | BIOCHEMISTRY & MOLECULAR BIOLOGY | SUBSTANCE ABUSE | SINGLE-NUCLEOTIDE POLYMORPHISM | GLUCOCORTICOIDS IN-VIVO | INDUCED BEHAVIORAL SENSITIZATION | RECOMBINANT GABA(A) RECEPTOR | CORTICOTROPIN-RELEASING-FACTOR | POSITRON-EMISSION-TOMOGRAPHY | MU-OPIOID-RECEPTOR | INDUCED DOPAMINE RELEASE | PITUITARY-ADRENAL AXIS | Neural Pathways - drug effects | Humans | Macaca mulatta | Substance-Related Disorders - genetics | Arousal - drug effects | gamma-Aminobutyric Acid - physiology | Dopamine - physiology | Neural Pathways - physiopathology | Alcoholism - physiopathology | Alcoholism - psychology | Hypothalamo-Hypophyseal System - physiopathology | Cues | Allostasis - physiology | Hypothalamo-Hypophyseal System - drug effects | Pituitary-Adrenal System - physiopathology | Arousal - genetics | Self Medication | Pituitary-Adrenal System - drug effects | Brain - physiopathology | Glucocorticoids - blood | Rats | Allostasis - drug effects | Substance-Related Disorders - physiopathology | Brain - drug effects | Corticotropin-Releasing Hormone - physiology | Arousal - physiology | Animals | Substance-Related Disorders - psychology | Alcoholism - genetics | Polymorphism, Genetic - genetics | Mice | Street Drugs - toxicity | Reward | Stress, Psychological - complications | Stress, Psychological - physiopathology | Complications and side effects | Medical colleges | Care and treatment | Corticosteroids | Drug interactions | Illegal drugs | Clinical trials | Substance abuse | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Pharmacokinetic drug–drug interactions between immunosuppressant and anti-infective agents: Antimetabolites and corticosteroids
by van Matre, Edwart T and Satyanarayana, Gowri and Page, Robert L and Levi, Marilyn E and Lindenfeld, Joann and Mueller, Scott W
Annals of Transplantation, ISSN 1425-9524, 2018, Volume 23, pp. 66 - 74
Infections account for 15-20% of deaths in transplant recipients, requiring rapid and appropriate therapeutic interventions. Many anti-infective agents... 
Anti-Infective agents | Corticosteroids | Antimetabolites | Drug interactions | SURGERY | INDUCED NONRESPONSIVENESS | STEROID-DEPENDENT ASTHMA | METHYLPREDNISOLONE ELIMINATION | Anti-Infective Agents | PROTEASE INHIBITORS | IATROGENIC CUSHING SYNDROME | TRANSPLANTATION | Drug Interactions | PLASMA-CONCENTRATIONS | HEART-TRANSPLANT RECIPIENT | BETA-GLUCURONIDASE | CORTISOL SECRETION | MYCOPHENOLATE-MOFETIL | Infection - drug therapy | Humans | Immunosuppressive Agents - pharmacokinetics | Immunosuppressive Agents - therapeutic use | Anti-Infective Agents - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Antimetabolites - therapeutic use | Infection - etiology | Anti-Infective Agents - pharmacokinetics | Organ Transplantation - adverse effects | Graft Rejection | Adrenal Cortex Hormones - pharmacokinetics | Antimetabolites - pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug–drug interaction study
by Belderbos, Bodine P.S and Hussaarts, Koen G.A.M and Harten, Leonie J and Oomen‐de Hoop, Esther and Bruijn, Peter and Hamberg, Paul and Alphen, Robbert J and Haberkorn, Brigitte C.M and Lolkema, Martijn P and Wit, Ronald and Soest, Robert J and Mathijssen, Ron H.J
British Journal of Clinical Pharmacology, ISSN 0306-5251, 05/2019, Volume 85, Issue 5, pp. 986 - 992
Aims Docetaxel has been approved for the treatment of metastatic prostate cancer in combination with prednisone. Since prednisone is known to induce the... 
drug–drug interaction | prednisone | docetaxel | metastatic prostate cancer | SURVIVAL | DEXAMETHASONE | MITOXANTRONE | PHASE-II | RECEPTOR | INDUCTION | TRIAL | TOXICITIES | THERAPY | PHARMACOLOGY & PHARMACY | drug-drug interaction | EXPRESSION | Corticosteroids | Medical examination | Drug interactions | Liver | Oncology, Experimental | Cytochrome P-450 | Docetaxel | Prednisone | Metastasis | Research | Drug approval | Blood | Liver cancer | Analysis | Drug therapy | Prostate cancer | Steroids | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Comparison of two endogenous biomarkers of CYP3A4 activity in a drug–drug interaction study between midostaurin and rifampicin
by Dutreix, Catherine and Lorenzo, Sebastien and Wang, Yanfeng
European Journal of Clinical Pharmacology, ISSN 0031-6970, 8/2014, Volume 70, Issue 8, pp. 915 - 920
Midostaurin, a multitargeted tyrosine kinase inhibitor, is primarily metabolized by CYP3A4. This midostaurin drug–drug interaction study assessed the dynamic... 
Biomedicine | Rifampicin | CYP3A4 biomarker | 6β-hydroxycortisol to cortisol ratio | Midostaurin | Pharmacology/Toxicology | 4β-hydroxycholesterol | RATIOS | MARKER | 6 beta-hydroxycortisol to cortisol ratio | HUMANS | MIDAZOLAM CLEARANCE | 4-BETA-HYDROXYCHOLESTEROL | INDUCTION | METABOLISM | INCREASE | URINARY 6-BETA-HYDROXYCORTISOL | 4 beta-hydroxycholesterol | PHARMACOLOGY & PHARMACY | CORTISOL | Protein Kinase Inhibitors - pharmacokinetics | Biomarkers - urine | Humans | Middle Aged | Staurosporine - blood | Hydrocortisone - urine | Male | Staurosporine - analogs & derivatives | Biomarkers - blood | Staurosporine - pharmacokinetics | Protein Kinase Inhibitors - blood | Hydrocortisone - analogs & derivatives | Young Adult | Cytochrome P-450 CYP3A Inducers - pharmacology | Drug Interactions | Cytochrome P-450 CYP3A - metabolism | Adult | Female | Hydroxycholesterols - blood | Rifampin - pharmacology | Complications and side effects | Corticosteroids | Comparative analysis | Biological markers | Rifampin | Cytochrome P-450 | Comparative studies | Biomarkers | Drug therapy | Cholesterol | Clinical Trial
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs
by Kakuda, Thomas N and Schöller-Gyüre, Monika and Hoetelmans, Richard M. W
Clinical Pharmacokinetics, ISSN 0312-5963, 1/2011, Volume 50, Issue 1, pp. 25 - 39
Etravirine (formerly TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against wild-type and NNRTI-resistant strains of HIV-1.... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Drug-interactions | Ribavirin, drug interactions | Antiepileptic-drugs, drug interactions | Simvastatin, drug interactions | Voriconazole, drug interactions | Dexamethasone, drug interactions | Fibric-acid-derivatives, drug interactions | Rifampicin, drug interactions | Opioid-analgesics, drug interactions | Antidepressants, drug interactions | Atorvastatin, drug interactions | Antiretrovirals, drug interactions | Anti-infectives, drug interactions | Histamine-H2-receptor-antagonists, drug interactions | Diazepam, drug interactions | Ketoconazole, drug interactions | Fluconazole, drug interactions | Hypericum, drug interactions | HMG-CoA-reductase-inhibitors, drug interactions | Oral-contraceptives, drug interactions | Sildenafil, drug interactions | Omeprazole, drug interactions | Buprenorphine, drug interactions | Rosuvastatin, drug interactions | Non-nucleoside-reverse-transcriptase-inhibitors, drug interactions | Type-5-cyclic-nucleotide- phosphodiesterase-inhibitors, drug interactions | Corticosteroids, drug interactions | Paroxetine, drug interactions | Fluoxetine, drug interactions | Rifapentine, drug interactions | Ethinylestradiolnorethisterone, drug interactions | Ranitidine, drug interactions | Etravirine, drug interactions | Antifungals, drug interactions | Digoxin, drug interactions | Warfarin, drug interactions | Methadone, drug interactions | Fluvastatin, drug interactions | Rifabutin, drug interactions | Sertraline, drug interactions | Azithromycin, drug interactions | Pharmacokinetics | Calcineurin-inhibitors, drug interactions | Itraconazole, drug interactions | Proton-pump-inhibitors, drug interactions | Clarithromycin, drug interactions | TRANSCRIPTASE INHIBITOR ETRAVIRINE | METABOLISM | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | HIV-NEGATIVE VOLUNTEERS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | HUMAN LIVER | PLACEBO-CONTROLLED TRIAL | 2 DIFFERENT FORMULATIONS | CLINICAL PHARMACOKINETICS | Reverse Transcriptase Inhibitors - adverse effects | Reverse Transcriptase Inhibitors - pharmacokinetics | Drug Interactions | Drug-Related Side Effects and Adverse Reactions | Humans | Pyridazines - pharmacokinetics | Drug Therapy, Combination | Pyridazines - adverse effects | Etravirine | Drug interactions | Physiological aspects | Dosage and administration | Research | Properties | Drug therapy | HIV infection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights